Unknown

Dataset Information

0

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment

ABSTRACT:

SUBMITTER: Herold S 

PROVIDER: S-EPMC12376325 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
| S-EPMC7065472 | biostudies-literature
Unknown Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax.
| S-EPMC10188502 | biostudies-literature
Unknown Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
| S-EPMC10278520 | biostudies-literature
Unknown Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
| S-EPMC7735159 | biostudies-literature
Unknown Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.
| S-EPMC12552230 | biostudies-literature
Unknown Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.
| S-EPMC12521056 | biostudies-literature
Unknown Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
| S-EPMC11561533 | biostudies-literature
Unknown Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
| S-EPMC8718245 | biostudies-literature
Unknown Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
| S-EPMC12927045 | biostudies-literature
Unknown Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
| S-EPMC4260975 | biostudies-literature